CKD
MCID: CHR684
MIFTS: 68

Chronic Kidney Disease (CKD)

Categories: Blood diseases, Bone diseases, Nephrological diseases

Aliases & Classifications for Chronic Kidney Disease

MalaCards integrated aliases for Chronic Kidney Disease:

Name: Chronic Kidney Disease 12 29 6 43 3 15 38 63 17 33
Chronic Renal Disease 12 15
Ckd 12 3
Chronic Renal Failure Syndrome 12
Renal Failure - Chronic 12
Kidney Failure, Chronic 44
Chronic Kidney Failure 12
Chronic Renal Failure 75
Renal Failure Chronic 55
Crf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:784
ICD9CM 35 585.6
MeSH 44 D007676
NCIt 50 C9438
SNOMED-CT 68 46177005 90688005
ICD10 33 N18 N18.9
UMLS 72 C0022661

Summaries for Chronic Kidney Disease

MedlinePlus : 43 You have two kidneys, each about the size of your fist. Their main job is to filter your blood. They remove wastes and extra water, which become urine. They also keep the body's chemicals balanced, help control blood pressure, and make hormones. Chronic kidney disease (CKD) means that your kidneys are damaged and can't filter blood as they should. This damage can cause wastes to build up in your body. It can also cause other problems that can harm your health. Diabetes and high blood pressure are the most common causes of CKD. The kidney damage occurs slowly over many years. Many people don't have any symptoms until their kidney disease is very advanced. Blood and urine tests are the only way to know if you have kidney disease. Treatments cannot cure kidney disease, but they may slow kidney disease. They include medicines to lower blood pressure, control blood sugar, and lower cholesterol. CKD may still get worse over time. Sometimes it can lead to kidney failure. If your kidneys fail, you will need dialysis or a kidney transplantation. You can take steps to keep your kidneys healthier longer: Choose foods with less salt (sodium) Control your blood pressure; your health care provider can tell you what your blood pressure should be Keep your blood sugar in the target range, if you have diabetes Limit the amount of alcohol you drink Choose foods that are healthy for your heart: fruits, vegetables, whole grains, and low-fat dairy foods Lose weight if you are overweight Be physically active Don't smoke NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Chronic Kidney Disease, also known as chronic renal disease, is related to renal osteodystrophy and end stage renal failure. An important gene associated with Chronic Kidney Disease is COL4A5 (Collagen Type IV Alpha 5 Chain), and among its related pathways/superpathways are p70S6K Signaling and PI3K-Akt signaling pathway. The drugs Nitric Oxide and Nifedipine have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are cardiovascular system and homeostasis/metabolism

CDC : 3 CKD is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke.

PubMed Health : 63 About chronic kidney disease: Our kidneys are vital organs that clean our blood and affect many different bodily functions. Various medical conditions can cause the kidneys to stop working properly for a short time – for example, if blood isn’t pumped around the body properly or if an enlarged prostate or kidney stones make urine build up in the kidneys. But if the kidneys still aren’t working at full capacity more than three months later or are permanently damaged, then the problem is considered to be chronic kidney disease. The most common causes in adults are diabetes and high blood pressure. Older people are especially prone to developing chronic kidney disease. It often goes unnoticed for a long time because poorly functioning kidneys don’t cause any problems at first. Treatment mostly aims to stop the kidney disease from getting worse, or at least delay the process. It is also important to treat complications such as anemia, acidosis or changes in bone metabolism. If the kidneys fail completely, dialysis or a kidney transplant can prolong the person’s life.

Wikipedia : 75 Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney... more...

Related Diseases for Chronic Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Renal Infectious Disease
Chronic Kidney Disease

Diseases related to Chronic Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1461)
# Related Disease Score Top Affiliating Genes
1 renal osteodystrophy 34.6 PTH FGF23 CASR
2 end stage renal failure 33.6 UMOD PTH NPHS2 IL6 EPO CST3
3 calciphylaxis 33.5 PTH FGF23 EPO CASR ALB
4 hypoparathyroidism 33.4 PTH FGF23 CASR
5 hyperparathyroidism 33.1 PTH FGF23 EPO CASR
6 deficiency anemia 32.9 IL6 EPO CRP ALB
7 renal tubular dysgenesis 32.9 REN AGTR1 ACE
8 hyperphosphatemia 32.9 PTH FGF23 CASR
9 microvascular complications of diabetes 3 32.8 INS ALB AGTR1 ACE
10 lipid metabolism disorder 32.7 INS CRP ACE
11 bone disease 32.7 PTH IL6 FGF23 CASR
12 peripheral vascular disease 32.5 IL6 CRP ALB ACE
13 uremia 32.5 PTH INS EPO CRP CASR ALB
14 hyperuricemia 32.5 UMOD REN INS CRP
15 congestive heart failure 32.5 REN EPO AGTR1 ACE
16 diabetes mellitus 32.4 TUG1 REN INS IL6 EPO CRP
17 vascular disease 32.3 REN INS IL6 CST3 CRP ALB
18 peripheral artery disease 32.3 IL6 CST3 CRP ACE
19 iron deficiency anemia 32.3 IL6 FGF23 EPO CRP
20 acute cystitis 32.2 IL6 CRP ALB
21 acute kidney failure 32.2 REN CST3 ALB
22 intermediate coronary syndrome 32.2 IL6 CRP ACE
23 coronary heart disease 1 32.2 INS IL6 CRP ACE
24 arteriosclerosis 32.2 INS IL6 CRP ACE
25 sleep disorder 32.2 INS IL6 CRP
26 hypertensive nephropathy 32.1 ALB AGTR1 ACE
27 arteries, anomalies of 32.1 REN INS IL6 CRP ALB AGTR1
28 glomerulonephritis 32.1 NPHS2 COL4A5 COL4A4 ALB
29 proteasome-associated autoinflammatory syndrome 1 32.1 INS IL6 CRP ALB
30 sleep apnea 32.0 REN INS IL6 CRP ACE
31 microvascular complications of diabetes 5 32.0 INS ALB AGTR1 ACE
32 kidney disease 32.0 UMOD REN PTH PKD2 NPHS2 INS
33 cerebrovascular disease 32.0 REN INS IL6 CRP AGTR1 ACE
34 angina pectoris 31.9 IL6 CRP ACE
35 pyelonephritis 31.9 UMOD IL6 CRP ALB ACE
36 interstitial nephritis 31.9 UMOD REN CRP ALB ACE
37 coronary stenosis 31.9 IL6 CRP ALB ACE
38 systolic heart failure 31.9 IL6 CST3 CRP ACE
39 heart disease 31.9 REN INS IL6 CST3 CRP ALB
40 osteomalacia 31.9 PTH FGF23 CASR
41 coronary artery anomaly 31.9 CRP AGTR1 ACE
42 acute kidney tubular necrosis 31.9 UMOD CST3 ALB
43 liver disease 31.8 PKD2 INS IL6 ALB
44 nephrocalcinosis 31.8 UMOD PTH CASR ALB
45 urinary tract obstruction 31.8 UMOD REN ALB
46 autosomal dominant polycystic kidney disease 31.8 REN PKD2 FGF23 CST3 ALB ACE
47 atherosclerosis susceptibility 31.8 TUG1 INS IL6 CRP
48 obstructive nephropathy 31.8 REN ALB ACE
49 nutritional deficiency disease 31.8 IL6 EPO CRP ALB
50 stroke, ischemic 31.8 REN CST3 CRP AGTR1 ACE

Graphical network of the top 20 diseases related to Chronic Kidney Disease:



Diseases related to Chronic Kidney Disease

Symptoms & Phenotypes for Chronic Kidney Disease

MGI Mouse Phenotypes related to Chronic Kidney Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ACE AGTR1 COL4A5 CRP CST3 EPO
2 homeostasis/metabolism MP:0005376 10.3 ACE AGTR1 ALB CASR COL4A4 COL4A5
3 growth/size/body region MP:0005378 10.22 ACE AGTR1 CASR COL4A4 FGF23 IL6
4 hematopoietic system MP:0005397 10.15 ACE AGTR1 CASR COL4A5 EPO FGF23
5 immune system MP:0005387 10.13 ACE AGTR1 CASR COL4A4 COL4A5 CRP
6 endocrine/exocrine gland MP:0005379 10.09 ACE ALB CASR FGF23 IL6 INS
7 digestive/alimentary MP:0005381 10.06 ALB CASR COL4A4 FGF23 IL6 INS
8 adipose tissue MP:0005375 9.97 ACE AGTR1 COL4A5 IL6 INS UMOD
9 mortality/aging MP:0010768 9.86 ACE AGTR1 ALB CASR COL4A4 COL4A5
10 liver/biliary system MP:0005370 9.7 ACE ALB EPO IL6 INS MKS1
11 renal/urinary system MP:0005367 9.47 ACE AGTR1 ALB CASR COL4A4 COL4A5

Drugs & Therapeutics for Chronic Kidney Disease

PubMed Health treatment related to Chronic Kidney Disease: 63

The most suitable treatment for chronic kidney disease will depend on the cause and stage of the disease, as well as on the person’s life circumstances and preferences. If the kidneys are still working at a nearly normal level, treatment should aim to stop or slow down the progression of the disease. This is mainly done using medication to lower blood pressure levels and prevent cardiovascular disease. If you have diabetes, it's important to regulate your blood sugar levels. If complications such as anemia or bone metabolism disorders have already occurred, then more medications are used – such as medicines that contain iron or stimulate the production of blood, as well as medications called “phosphate binders.” If there is too much acid in your body, bicarbonates are used. In addition to the medication, the treatment will include a diet suited to the stage of the disease, drinking the right amounts of liquids and physical exercise. Dialysis or a kidney transplant are considered if the kidneys fail completely. In the vast majority of people with complete kidney failure, at least one of these options is possible. Some people make a conscious decision not to use either, accepting the fact that they could die soon afterwards. Palliative treatment may then be suitable for them – enabling a final phase of life that is as pleasant as possible.

Drugs for Chronic Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 843)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Nifedipine Approved Phase 4 21829-25-4 4485
3
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
4
Fosinopril Approved Phase 4 98048-97-6 55891
5
Enoxaparin Approved Phase 4 9005-49-6 772
6
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
7
Digoxin Approved Phase 4 20830-75-5 30322 2724385
8
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
9
Methyldopa Approved Phase 4 555-30-6 38853
10
Indapamide Approved Phase 4 26807-65-8 3702
11
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
12
Capsaicin Approved Phase 4 404-86-4 1548943
13
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
14
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
15
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
16
Cinacalcet Approved Phase 4 226256-56-0 156419
17
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
18
Tinzaparin Approved Phase 4 9005-49-6, 9041-08-1 25244225
19
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
20
Telavancin Approved Phase 4 372151-71-8
21
Zidovudine Approved Phase 4 30516-87-1 35370
22
Azathioprine Approved Phase 4 446-86-6 2265
23
Ramipril Approved Phase 4 87333-19-5 5362129
24
Dalteparin Approved Phase 4 9005-49-6
25
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
26
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
27
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
28
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
29
Deflazacort Approved, Investigational Phase 4 14484-47-0
30
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
31
Amlodipine Approved Phase 4 88150-42-9 2162
32
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
33
Dolutegravir Approved Phase 4 1051375-16-6 54726191
34
Apixaban Approved Phase 4 503612-47-3 10182969
35 Taurolidine Approved, Investigational Phase 4 19388-87-5
36
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
37
Colchicine Approved Phase 4 64-86-8 6167 2833
38
Iodine Approved, Investigational Phase 4 7553-56-2 807
39
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
40
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
41
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
42
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
43
Aminophylline Approved Phase 4 317-34-0 9433
44
Liraglutide Approved Phase 4 204656-20-2 44147092
45
alemtuzumab Approved, Investigational Phase 4 216503-57-0
46
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
47
Racepinephrine Approved Phase 4 329-65-7 838
48
Insulin glargine Approved Phase 4 160337-95-1
49
Rilonacept Approved, Investigational Phase 4 501081-76-1 104924
50
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754

Interventional clinical trials:

(show top 50) (show all 3703)
# Name Status NCT ID Phase Drugs
1 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
2 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
3 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Unknown status NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
4 Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial Unknown status NCT01347775 Phase 4
5 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
6 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
7 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
8 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction—a Multicentre, Single Blind, Randomized Controlled, Prospective Trial Unknown status NCT01580046 Phase 4 iodixanol;iopromide
9 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
10 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
11 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
12 Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
13 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
14 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
15 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
16 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
17 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
18 Immunosuppression in Renal Transplantation in The Elderly: Time to Rethink. - nEverOld Study Unknown status NCT01631058 Phase 4 Everolimus
19 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
20 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
21 Randomized Open Clinical Trial to Compare the Effectiveness of the Administration of Diuretics in Hemodialysis Patients With Residual Renal Function in Single Centre Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
22 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
23 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
24 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
25 Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Unknown status NCT01442272 Phase 4 Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
26 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
27 Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes Unknown status NCT01635387 Phase 4 aliskiren
28 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease:a Multicentre Open Study Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
29 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
30 Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease Unknown status NCT00719316 Phase 4 Aliskiren
31 Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4) Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
32 Canadian Collaborative Group for the Prevention of Illness in Chronic Renal Disease. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
33 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
34 Comparison of the Effects Between Keto-/Amino Acid Supplemented Low Protein Diet and Non-Supplemented Low Protein Diet in Patients With Stage Ⅴ Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
35 Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Unknown status NCT02792413 Phase 4 Denosumab;NaCl (placebo)
36 The Association Between Body Composition and Biomarkers in Hemodialysis Patients Unknown status NCT01103167 Phase 4
37 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
38 Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
39 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
40 Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
41 Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD Unknown status NCT01820832 Phase 4 Calcitriol
42 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
43 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
44 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
45 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
46 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
47 Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients Unknown status NCT00532597 Phase 4
48 Intradialytic Exercise for Enhanced Dialysis Adequacy and Solute Removal in Chronic Kidney Disease Patients: A Randomised Controlled Trial. Unknown status NCT01481688 Phase 4
49 Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement Unknown status NCT03121053 Phase 4 sodium bicarbonate;hypotone saline
50 Low-molecular Heparin Infusion as Anticoagulation for Nocturnal Home Hemodialysis Unknown status NCT02957877 Phase 4 Nadroparin;Unfractionated heparin

Search NIH Clinical Center for Chronic Kidney Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Kidney Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: kidney failure, chronic

Genetic Tests for Chronic Kidney Disease

Genetic tests related to Chronic Kidney Disease:

# Genetic test Affiliating Genes
1 Chronic Kidney Disease 29

Anatomical Context for Chronic Kidney Disease

MalaCards organs/tissues related to Chronic Kidney Disease:

41
Kidney, Bone, Heart, Endothelial, Liver, Testes, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Chronic Kidney Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Kidney Proximal Tubule Proximal Tubule Cells Affected by disease, potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Chronic Kidney Disease

Articles related to Chronic Kidney Disease:

(show top 50) (show all 34238)
# Title Authors PMID Year
1
Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. 38 17
31335677 2019
2
Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis. 38 17
31261559 2019
3
Optimal cut-off threshold in pulse pressure predicting cardiovascular death among newly diagnosed end-stage renal disease patients: A prospective cohort study. 17
31277187 2019
4
A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. 9 38
19929273 2010
5
Insulin resistance as a novel therapeutic target in patients with chronic kidney disease treated with dialysis. 9 38
20150846 2010
6
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. 9 38
19347366 2009
7
Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. 9 38
20025585 2009
8
[BNP and echocardiographic parameters in patients with chronic kidney disease and dialyzed patients]. 9 38
19947237 2009
9
Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. 9 38
19535427 2009
10
Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. 9 38
19083024 2009
11
Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD). 9 38
19297356 2009
12
Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. 9 38
19460838 2009
13
Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. 9 38
19138652 2009
14
Insulin resistance in chronic uremia. 9 38
19121765 2009
15
New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. 9 38
19494617 2009
16
Leptin and lipid metabolism in chronic kidney failure. 9 38
19148833 2009
17
Familial juvenile hyperuricemic nephropathy: report on a new mutation and a pregnancy. 9 38
19203555 2009
18
[Insulin resistance and chronic kidney disease]. 9 38
18514051 2008
19
Vitamin D: an old prohormone with an emergent role in chronic kidney disease. 9 38
18587719 2008
20
[Peritoneal dialysis and insulin resistance in patients with chronic kidney disease due to nondiabetic nephropathy]. 9 38
18634374 2008
21
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. 9 38
18094675 2008
22
BNP and a renal patient: emphasis on the unique characteristics of B-type natriuretic peptide in end-stage kidney disease. 9 38
18451660 2008
23
Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure. 9 38
18923754 2008
24
Association between vitamin D receptor gene polymorphisms and susceptibility to chronic kidney disease and periodontitis. 9 38
17914260 2007
25
Adiponectin and chronic kidney disease. 9 38
17198925 2007
26
Stature in children with chronic kidney disease: analysis of NAPRTCS database. 9 38
16583244 2006
27
Arginine, arginine analogs and nitric oxide production in chronic kidney disease. 9 38
16932427 2006
28
FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. 9 38
16691036 2006
29
Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. 9 38
16257266 2006
30
Biomarkers in chronic kidney disease: utility and issues towards better understanding. 9 38
16205471 2005
31
[Early diagnosis of chronic kidney diseases]. 9 38
15742164 2005
32
Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. 9 38
15585515 2005
33
Association of TGF-beta1 polymorphisms with chronic renal disease. 9 38
15593053 2004
34
Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. 9 38
15200442 2004
35
[Biological activity of FGF-23 and pathophysiologic role in chronic kidney disease]. 9 38
15577039 2004
36
Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. 9 38
15090865 2004
37
Vascular calcification in chronic kidney disease. 9 38
14730511 2004
38
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. 9 38
14633152 2003
39
Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease? 9 38
14681862 2003
40
Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients. 9 38
11812876 2002
41
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. 9 38
11453706 2001
42
Urinary excretion of vasoactive substances in chronic renal failure. 9 38
11393385 2001
43
Serum hepatocyte growth factor levels in patients with chronic renal disease--effect of GFR and pathogenesis. 9 38
11768321 2001
44
Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. 9 38
10739792 2000
45
Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. 9 38
10219067 1999
46
The effect of metabolic acidosis on serum apolipoprotein A I and apolipoprotein B levels in children with chronic renal failure. 9 38
9413770 1997
47
Endothelial function and the kidney. An emerging target for cardiovascular therapy. 9 38
9034751 1997
48
Role of lipid peroxidation, trace elements and anti-oxidant enzymes in chronic renal disease patients. 9 38
9071084 1996
49
The changes in serum type I and III procollagen, insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels in children with chronic renal failure. 9 38
8936957 1996
50
Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. 9 38
15387752 1996

Variations for Chronic Kidney Disease

ClinVar genetic disease variations for Chronic Kidney Disease:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PKD2 NM_000297.4(PKD2): c.357_364delinsTAGGACG (p.Pro120fs) indel Pathogenic rs1057518797 4:88929242-88929249 4:88008090-88008097
2 COL4A5 NM_000495.5(COL4A5): c.3614G> T (p.Gly1205Val) single nucleotide variant Pathogenic rs1556446493 X:107911558-107911558 X:108668328-108668328
3 MKS1 NM_017777.3(MKS1): c.1115_1117del (p.Ser372del) deletion Pathogenic/Likely pathogenic rs754279998 17:56285514-56285516 17:58208153-58208155
4 SLC13A5 NM_177550.4(SLC13A5): c.231+2T> G single nucleotide variant Likely pathogenic rs730882222 17:6610345-6610345 17:6707026-6707026
5 CEL NM_001807.5(CEL): c.1966G> C (p.Ala656Pro) single nucleoti